Genmab A/S (GMAB): price, analyst ratings, earnings and fundamentals
Updated 30 October 2026, 21:45 ET
Genmab A/S (GMAB) closed at $57.06 on 30 October 2026, up 1.0%. The stock is up 65.2% over one month and up 97.1% over one year. It trades 4.9% below its 52-week high of $59.97. Analysts recorded 12 actions in the last 90 days; the median price target of $67 is 17.4% above the last close. The company last reported on 6 August 2026 for Q2 2026: EPS of $4.91 against an estimate of $0.31, a beat of 1483.9%, on revenue of $1.2 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open GMAB in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 12 analyst actions on GMAB from 6 firms: 11 maintained or reiterated a view and 1 upgrade. Price targets were 10 raised. The most recent targets from 5 firms range from $52 to $80, with a median of $67, 17.4% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 30 Oct 2026 | Morgan Stanley | Maintains Equal-Weight | $42.00 to $57.00 |
| 30 Oct 2026 | Guggenheim | Maintains Buy | $58.00 to $80.00 |
| 29 Oct 2026 | Truist Securities | Reiterates Buy | $45.00 to $67.00 |
| 29 Oct 2026 | HC Wainwright & Co. | Maintains Buy | $50.00 to $70.00 |
| 26 Oct 2026 | TD Cowen | Maintains Buy | $43.00 to $52.00 |
| 26 Oct 2026 | JP Morgan | Upgrades to Overweight from Neutral | |
| 7 Oct 2026 | Truist Securities | Maintains Buy | $40.00 to $45.00 |
| 7 Oct 2026 | Guggenheim | Maintains Buy | $54.00 to $58.00 |
| 7 Oct 2026 | HC Wainwright & Co. | Maintains Buy | $40.00 to $50.00 |
| 5 Oct 2026 | Guggenheim | Maintains Buy | $45.00 to $54.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 5 November 2026 during the session for Q3 2026, with EPS expected at $0.33 on revenue of $6.7 billion. Genmab A/S beat the EPS estimate in 5 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 6 Aug 2026 | $0.31 | $4.91 | +1483.87% | $1.2B |
| Q1 2026 | 7 May 2026 | $0.17 | $0.08 | -51.18% | $896.0M |
| Q4 2025 | 17 Feb 2026 | $0.44 | $0.05 | -88.64% | $1.1B |
| Q3 2025 | 6 Nov 2025 | $0.46 | $0.65 | +40.43% | $1.0B |
| Q2 2025 | 7 Aug 2025 | $0.36 | $0.54 | +50.56% | $925.0M |
| Q1 2025 | 8 May 2025 | $0.23 | $0.31 | +34.78% | $715.0M |
| Q4 2024 | 12 Feb 2025 | $0.28 | $0.85 | +203.57% | $921.6M |
| Q3 2024 | 6 Nov 2024 | $0.35 | $0.29 | -17.14% | $816.0M |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
On a trailing twelve month basis the company shows revenue growth of 30.67%, a gross margin of 95.42%, an operating margin of 31.14% and a return on equity of 22.97%.
Assets
| Line | Amount |
|---|---|
| Cash & Cash Equivalents | $9,858,000,000 |
| Accounts & Notes Receivable, Net | $6,590,000,000 |
| Other Receivables | $353,000,000 |
| Inventory | $62,000,000 |
| Total Current Assets | $27,854,000,000 |
| Plant, Property & Equipment, Net | $978,000,000 |
| Goodwill Intangible Assets, Net | $14,878,000,000 |
| Total Assets | $45,811,000,000 |
Liabilities and equity
| Line | Amount |
|---|---|
| Total Current Liabilities | $5,308,000,000 |
| Total Liabilities | $9,114,000,000 |
| Retained Earnings | $23,551,000,000 |
| Total Stockholders Equity | $36,697,000,000 |
| Total Liability & Stockholders Equity | $45,811,000,000 |
Figures as filed with the SEC for the period ended 31 December 2024, in US dollars.
FundSpec fundamental metrics
Each metric is computed from the company's filings and ranked against every company FundSpec covers; the percentile is the share of covered companies with a lower value.
Liquidity
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Cash Ratio | 1.86 | 83rd | Calculated as the ratio of Cash and cash equivalents / Current liabilities. This metric calculates the company's ability to repay its short-term debt |
| Current Ratio | 5.25 | 88th | Calculated as the ratio of Current Assets / Current Liabilities. The higher the current ratio, the more capable the company is of paying its obligations |
| Quick Ratio | 3.10 | 87th | Calculated as the ratio of (Cash + Marketable Securities + Accounts Receivable) / Current Liabilities. The quick ratio is a measure of how well a company can meet its short-term financial liabilities. |
Leverage
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Debt/Assets | 0.00 | 17th | Calculated as the ratio of Short-Term Debt + Long-Term Debt / Total Assets. The higher the ratio, the higher the degree of leverage, and consequently, financial risk |
| Debt/Equity | 0.00 | 14th | Calculated as the ratio of Total Liabilities / Shareholders' Equity. The ratio indicates how much debt a company is using to finance its assets relative to the amount of value represented in shareholders’ equity |
| Degree of Combined Leverage | 1.20 | 59th | This ratio summarizes the combined effect that the degree of operating leverage (DOL) and the degree of financial leverage have on earnings per share (EPS), given a particular change in sales |
| Degree of Financial Leverage | 1.42 | 82nd | Calculated as the ratio of Percentage change in EPS / Percentage change in EBIT. A higher degree of financial leverage means that the company has more volatile EPS. |
| Degree of Operational Leverage | 0.85 | 56th | Calculated as the ratio of Percentage change in EBIT / Percentage change in revenue. It is a measure of how earnings for the company is impacted by its sales activity. |
Earnings Growth (EBIT)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| EBIT Pct Growth | 26.0% | 98th | The EBIT growth rate over the trailing twelve months (TTM) |
| EBIT Pct Growth 3 year CAGR | 31.4% | 32nd | The EBIT compound annual growth rate (CAGR) over the past 3 years |
Profitability
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Free Cashflow Margin Pct | 35.2% | 93rd | Calculated as the ratio of Free Cashflow from Operating Activities / Net Sales. It measures how much per dollar of revenue the company is able to convert into free cash flow. |
| Gross Margin Pct | 95.4% | 98th | Calculated as the ratio of Revenue - Cost of Goods Sold (COGS) / Revenue. The gross margin represents the percent of total sales revenue that the company retains after incurring the direct costs associated with producing the goods and services sold by a company. |
| Operating Margin Pct | 31.1% | 90th | Calculated as the ratio of (Revenue - (Cost of Goods Sold + Labour + Sales, General & Administrative)) / Revenue. Operating margins are important because they measure efficiency. The higher the operating margin, the more profitable a company's core business is. |
| Operating Profit Pct Growth | 26.0% | 65th | The Operating Profit growth rate over the trailing twelve months (TTM) |
| Operating Profit Pct Growth 3 year CAGR (FY) | 31.4% | 84th | The Operating Profit compound annual growth rate (CAGR) over the past 3 years |
| Operating Profit Pct Growth 5 year CAGR (FY) | 20.5% | 81st | The Operating Profit compound annual growth rate (CAGR) over the past 5 years |
| PreTax Margin Pct | 42.6% | 93rd | Calculated as the ratio of (Gross profit - (Operating Expense + Interest Expense)) / Revenue. The pretax profit margin enables profitability to be compared across companies with significant differences in size, scale, capital structure and tax rates. |
| Return on Assets Pct | 19.3% | 96th | Calculated as the ratio of Net Income / Total Assets. It is an indicator of how efficient the company is at using its assets to generate earnings. |
| Return on Equity Pct | 23.0% | 88th | Calculated as the ratio of Net Income / Shareholders' equity. It is a measure of how much profit a company generates with the money shareholders have invested. |
| Return on Invested Capital Pct | 16.8% | 86th | Calculated as the ratio of (Net Income - Dividends) / (Debt + Equity). It is a measure of how efficient the company is at allocating the capital under its control to profitable investments. |
Cashflow
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| FCF Pct Growth | 8.1% | 50th | The Free Cash Flow growth rate over the trailing twelve months (TTM) |
| FCF Pct Growth 3 year CAGR | 283.8% | 89th | The Free Cash Flow compound annual growth rate (CAGR) over the past 3 years |
| FCF Pct Growth 5 year CAGR | 400.0% | 94th | The Free Cash Flow compound annual growth rate (CAGR) over the past 5 years |
| FCF Return on Assets Pct | 18.7% | 95th | Calculated as the ratio of Cashflow from Operations / Total Assets. A high cash return on assets means a company is generating more cash flow from every asset dollar |
| Operating Cashflow Pct Growth | 5.3% | 49th | The Operating Cashflow growth rate over the trailing twelve months (TTM) |
| Operating Cashflow Pct Growth 3 year CAGR (FY) | 51.7% | 93rd | The Operating Cashflow compound annual growth rate (CAGR) over the past 3 years |
| Operating Cashflow Pct Growth 5 year CAGR (FY) | 42.4% | 95th | The Operating Cashflow compound annual growth rate (CAGR) over the past 5 years |
Earnings Growth (Net Income)
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Net Income Pct Growth | 80.2% | 79th | The Net Income growth rate over the trailing twelve months (TTM) |
| Net Income Pct Growth 3 year CAGR | 38.4% | 87th | The Net Income compound annual growth rate (CAGR) over the past 3 years |
| Net Income Pct Growth 5 year CAGR | 29.4% | 88th | The Net Income compound annual growth rate (CAGR) over the past 5 years |
Top Line Growth
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Revenue Pct Growth | 30.7% | 83rd | The Revenue (Sales) growth rate over the trailing twelve months (TTM) |
| Revenue Pct Growth 3 year CAGR | 36.8% | 91st | The Revenue (Sales) compound annual growth rate (CAGR) over the past 3 years |
| Revenue Pct Growth 5 year CAGR | 32.0% | 90th | The Revenue (Sales) compound annual growth rate (CAGR) over the past 5 years |
Taxes
| Metric | Value | Percentile | What it measures |
|---|---|---|---|
| Effective Tax Rate Pct | 14.4% | 57th | The effective tax rate of the company over the trailing twelve months (TTM). |
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open GMAB in FundSpec.
SEC filings
The latest filing is a 20-F from 17 February 2026.
| Filed | Form | Document |
|---|---|---|
| 17 Feb 2026 | 20-F | View on sec.gov |
| 12 Feb 2025 | 20-F | View on sec.gov |
| 14 Feb 2024 | 20-F | View on sec.gov |
| 22 Feb 2023 | 20-F | View on sec.gov |
| 16 Feb 2022 | 20-F | View on sec.gov |
| 29 Mar 2021 | 20-F | View on sec.gov |
| 30 Mar 2020 | 20-F | View on sec.gov |
Company profile
- Exchange
- Nasdaq
- Sector
- Pharmaceuticals, Biotech and Chemicals
- Industry
- Pharmaceutical Products
- Headquarters
- 1253 COPENHAGEN K, Denmark
- Chief executive
- Jan G. J. van de Winkel
- Employees
- 1,660
- Website
- genmab.com
- SEC CIK
- 0001434265
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.
Sector and peers
Genmab A/S is part of the Pharmaceuticals, Biotech and Chemicals sector, which FundSpec tracks across 609 companies.
Companies in the same industry by market capitalization:
PG Procter & Gamble Co.NVO Novo Nordisk A SUL Unilever PLCSNY SanofiGSK GSK plcECL Ecolab Inc.TAK Takeda Pharmaceutical Co. Ltd.ARGX argenx SE
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for GMAB are available to subscribers, with the same screen in the iOS and Android apps.
Open GMAB in FundSpec